Evidence map›Paper›PMID 38496444›Full record

ArticlebioRxiv : the preprint server for biology2025

Lipid Peroxidation and Type I Interferon Coupling Fuels Pathogenic Macrophage Activation Causing Tuberculosis Susceptibility.

Shivraj M Yabaji, Vadim Zhernovkov, Prasanna Babu Araveti, Suruchi Lata, Oleksii S Rukhlenko, Salam Al Abdullatif, Arthur Vanvalkenburg, Yuriy Alekseev, Qicheng Ma, Gargi Dayama and 9 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 2 countries.

Shivraj M YabajiThe National Emerging Infectious Diseases Laboratory, Boston University, Boston, MA.ORCID 0000-0002-5793-1661
Vadim ZhernovkovSystems Biology Ireland, School of Medicine, University College Dublin, Dublin 4, Ireland.
Prasanna Babu AravetiThe National Emerging Infectious Diseases Laboratory, Boston University, Boston, MA.ORCID 0000-0002-5441-3826
Suruchi LataThe National Emerging Infectious Diseases Laboratory, Boston University, Boston, MA.ORCID 0000-0001-5548-9315
Oleksii S RukhlenkoSystems Biology Ireland, School of Medicine, University College Dublin, Dublin 4, Ireland.ORCID 0000-0003-1863-4987
Salam Al AbdullatifDepartment of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA.
Arthur VanvalkenburgRutgers University, New Jersey Medical School, Division of Infectious Disease, Department of Medicine.ORCID 0009-0007-1793-9160
Yuriy AlekseevThe Department of Pathology and Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02118.
Qicheng MaDepartment of Biochemistry, and Cell Biology and Genome Science Institute, Boston University Chobanian & Avedisian School of Medicine.
Gargi DayamaDepartment of Biochemistry, and Cell Biology and Genome Science Institute, Boston University Chobanian & Avedisian School of Medicine.
Nelson C LauThe National Emerging Infectious Diseases Laboratory, Boston University, Boston, MA.ORCID 0000-0001-9907-1404
W Evan JohnsonRutgers University, New Jersey Medical School, Division of Infectious Disease, Department of Medicine.
William R BishaiCenter for TB Research, Johns Hopkins School of Medicine, Baltimore, Maryland.ORCID 0000-0002-8734-4118
Nicholas A CrosslandThe National Emerging Infectious Diseases Laboratory, Boston University, Boston, MA.ORCID 0000-0003-3873-9188
Joshua D CampbellDepartment of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA.
Boris N KholodenkoSystems Biology Ireland, School of Medicine, University College Dublin, Dublin 4, Ireland.ORCID 0000-0002-9483-4975
Alexander A GimelbrantAltius Institute for Biomedical Sciences, Seattle, WA, USA.ORCID 0000-0001-6986-0285
Lester KobzikCellecta, Inc., Mountain View, CA.ORCID 0000-0003-4328-937X
Igor KramnikThe National Emerging Infectious Diseases Laboratory, Boston University, Boston, MA.ORCID 0000-0001-6511-9246
Boston University · USUniversity College Dublin · IERutgers, The State University of New Jersey · USAltius Institute for Biomedical Sciences · USCellecta (United States) · USJohns Hopkins University · US

Funding

Necrosis in pulmonary TB granulomas: dynamics, mechanisms, therapiesR01HL126066 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KRAMNIK, IGOR, NIEDERWEIS, MICHAEL · 2016 to 2025
$5.6M
Mechanism and function of autosomal analog of X inactivationR01GM114864 · NIGMS · DANA-FARBER CANCER INST · PI GIMELBRANT, ALEXANDER · 2014 to 2018
$4.9M
Transposable Element (TE) RNA regulation via small RNA pathways in aging cells and neurodegeneration.R01AG078930 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI NELSON C LAU · 2022 to 2026
$3.5M
Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway SignalingR01CA244660 · NCI · YALE UNIVERSITY · PI HLAVACEK, WILLIAM S, KHOLODENKO, BORIS N · 2020 to 2024
$3.4M
Aberrant immune activation in the tuberculosis granuloma: a pivotal role in necrosisR01HL133190 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI BISHAI, WILLIAM RAMSES, KRAMNIK, IGOR · 2016 to 2019
$3.0M
Toxin secretion and trafficking by Mycobacterium tuberculosisR01AI175106 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MICHAEL NIEDERWEIS · 2023 to 2026
$3.0M
Removing batch effects in high-throughput biomedical studiesR01GM127430 · NIGMS · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI William Evan Johnson · 2018 to 2026
$2.4M
Transposon landscapes and transcriptome diversity in aging neuronsR01AG052465 · NIA · BRANDEIS UNIVERSITY · PI LAU, NELSON C · 2016 to 2020
$2.0M
The interplay between transposons and piRNA pathways.R01GM135215 · NIGMS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LAU, NELSON C · 2020 to 2023
$1.8M
Integrative clustering of cells and samples using multi-modal single-cell dataR01LM013154 · NLM · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CAMPBELL, JOSHUA D, YAJIMA, MASANAO · 2019 to 2021
$1.1M
NCI NIH HHS R01 CA244660NHLBI NIH HHS R01 HL126066NHLBI NIH HHS R01 HL133190NIAID NIH HHS R01 AI175106NIA NIH HHS R01 AG052465NIA NIH HHS R01 AG078930NIGMS NIH HHS R01 GM114864NIGMS NIH HHS R01 GM127430NIGMS NIH HHS R01 GM135215NLM NIH HHS R01 LM013154
6 · The paper itself

Abstract

A quarter of human population is infected with Mycobacterium tuberculosis, but less than 10% of those infected develop pulmonary TB. We developed a genetically defined sst1-susceptible mouse model that uniquely reproduces a defining feature of human TB: the development of necrotic lung granulomas and determined that the sst1-susceptible phenotype was driven by the aberrant macrophage activation. This study demonstrates that the aberrant response of the sst1-susceptible macrophages to prolonged stimulation with TNF is primarily driven by conflicting Myc and antioxidant response pathways leading to a coordinated failure 1) to properly sequester intracellular iron and 2) to activate ferroptosis inhibitor enzymes. Consequently, iron-mediated lipid peroxidation fueled

Indexed as

antioxidant defenseinflammationlipid peroxidationmacrophageMyctuberculosistype I interferon

Identifiers

PMID38496444
PMCPMC10942339
OpenAlexW4392650306

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.